Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Science Group raises Ricardo stake, has 'little confidence' in board

(Sharecast News) - Science and technology consultancy Science Group revealed on Tuesday that it had raised its stake in environmental consulting services firm Ricardo to 14.49m shares, representing approximately 20.08% of the company's total voting rights. Science Group stated the 20% threshold was "a key strategic investment milestone", achieved in just 7 weeks, at an average cost of 236.0p per share. The AIM-listed group stated it "may or may not "increase its shareholding in Ricardo.

"The Science Group shareholding was acquired at levels last seen in 2010 following disappointing Ricardo operating performance and investor loss of confidence," said Science Group, which added that since Ricardo's board "was evidently unable to manage the company through the 'market headwinds' of 2024", it now has "little confidence" in its ability to "navigate the global storms" developing in 2025.

"Science Group considers it extraordinary that, with such poor operating performance compounded by ineffective governance, the Ricardo Board refuses to accept responsibility. The chairman is ultimately accountable to shareholders for the destruction of shareholder value and his position is clearly untenable," it said.

"In light of the recent market/economic volatility, increasing significantly in the past week, the need to effect change at Ricardo is even more pressing. The future strategy now needs to be defined by a realigned board, reflecting the current market environment and a reprioritisation of shareholders' interests."

As of 0910 BST, Ricardo shares were up 3.04% at 237.00p, while Science Group shares advanced 3.19% to 420.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.